Literature DB >> 9637769

The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype.

V Sung1, C Gilles, A Murray, R Clarke, A D Aaron, N Azumi, E W Thompson.   

Abstract

We have characterized the LCC15-MB cell line which was recently derived from a breast carcinoma metastasis resected from the femur of a 29-year-old woman. LCC15-MB cells are vimentin (VIM) positive, exhibit a stellate morphology in routine cell culture, and form penetrating colonies when embedded in three-dimensional gels of Matrigel or fibrillar collagen. They show high levels of activity in the Boyden chamber chemomigration and chemoinvasion assays, and like other invasive human breast cancer (HBC) cell lines, LCC15-MB cells activate matrix-metalloproteinase-2 in response to treatment with concanavalin A. In addition, these cells are tumorigenic when implanted subcutaneously in nude mice and recolonize bone after arterial injection. Interestingly, both the primary lesion and the bone metastasis from which LCC15-MB were derived, as well as the resultant cell line, abundantly express the bone matrix protein osteopontin (OPN). OPN is also expressed by the highly metastatic MDA-MB-435 cells, but not other invasive or noninvasive HBC cell lines. Expression of OPN is retained in the subcutaneous xenograft and intraosseous metastases of LCC15-MB as detected by immunohistochemistry. Both VIM and OPN expression have been associated with breast cancer invasion and metastasis, and their expression by the LCC15-MB cell line is consistent with its derivation from a highly aggressive breast cancer. These cells provide a useful model for studying molecular mechanisms important for breast cancer metastasis to bone and, in particular, the implication(s) of OPN and VIM expression in this process. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637769     DOI: 10.1006/excr.1998.4029

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines.

Authors:  Erik W Thompson; Mark Waltham; Susan J Ramus; Anne-Marie Hutchins; Jane E Armes; Ian G Campbell; Elizabeth D Williams; Phillip R Thompson; James M Rae; Michael D Johnson; Robert Clarke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

2.  Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer.

Authors:  Guoxin Zhang; Bin He; Georg F Weber
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

3.  Differential expression of tartrate-resistant acid phosphatase isoforms 5a and 5b by tumor and stromal cells in human metastatic bone disease.

Authors:  Serhan Zenger; Wentao He; Barbro Ek-Rylander; Daphne Vassiliou; Rickard Wedin; Henrik Bauer; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2010-10-22       Impact factor: 5.150

Review 4.  The role of osteopontin in breast cancer: clinical and experimental studies.

Authors:  A B Tuck; A F Chambers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

Review 5.  Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.

Authors:  R M Hoffman
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

6.  Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry.

Authors:  C M Schmidt; S L Settle; J L Keene; W F Westlin; G A Nickols; D W Griggs
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

7.  Osteopontin expression in squamous cell cancer of the esophagus.

Authors:  I-Chen Wu; Ming-Tsang Wu; Shah-Hwa Chou; Sheau-Fang Yang; Yih-Gang Goan; Jang-Ming Lee; Yi-Pin Chou; Ming-Jong Bair; Tsang-En Wang; Angela Chen; Wen-Hsiung Chang; Fu-Chen Kuo; Deng-Chyang Wu
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

Review 8.  Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter.

Authors:  David T Denhardt; Devra Mistretta; Ann F Chambers; Shuba Krishna; Joseph F Porter; Srilatha Raghuram; Susan R Rittling
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.

Authors:  Gabriele Carlinfante; Daphne Vassiliou; Olle Svensson; Mikael Wendel; Dick Heinegård; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.

Authors:  Jessica Wang-Rodriguez; Virginia Urquidi; Amber Rivard; Steve Goodison
Journal:  Breast Cancer Res       Date:  2003-07-09       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.